Company Profile
Repligen Stock Price, News & Analysis
- Ticker:
- RGEN
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Repligen is followed within the biotech universe for its exposure to catalyst-driven execution.
Stock performance
126.37 USD (-0.16%)
Close
Last updated: June 23, 2026 at 00:00
7.13B USD
Market cap
Why the stock is moving
RGEN is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Repligen is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Repligen is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Repligen follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Repligen sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Repligen (RGEN)?
Repligen (RGEN) most recently closed at 126.37 USD, a -0.16% move versus the previous session.
What is the market cap of Repligen (RGEN)?
Repligen currently has a market capitalization of 7.13B USD on BioPharmSignal.
What does Repligen do?
Repligen is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
On which exchange is RGEN stock listed?
Repligen (RGEN) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Repligen is followed within the biotech universe for its exposure to catalyst-driven execution., Biotechnology.
What is Repligen?
Repligen is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs.
Which conditions is Repligen targeting with Repligen?
Repligen is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
What is Investors?
Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.